Oxaliplatine Hospira (Oxaliplatin)

Oxaliplatin exerts its antitumor effect by forming covalent cross‑links between DNA bases, especially guanine. These cross‑links prevent DNA replication and transcription, leading to cell‑cycle arrest and programmed cell death in rapidly dividing cancer cells, particularly those of colorectal origin.

The specific dose of Oxaliplatine Hospira is determined by the prescribing oncologist based on factors such as body surface area, disease stage, and combination therapy. Dosing regimens are individualized and administered under professional medical supervision.

Safety of oxaliplatin during pregnancy and lactation has not been established. It is generally contraindicated for pregnant or nursing women because potential risks to the fetus or infant cannot be ruled out. Physicians should discuss alternative options when treatment is needed in these populations.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Oxaliplatin belongs to the platinum‑based class but differs from cisplatin and carboplatin in its side‑effect profile. It tends to cause less nephrotoxicity and ototoxicity than cisplatin but has a higher incidence of peripheral neuropathy. Its efficacy in colorectal cancer is well‑established, making it a preferred choice in many regimens.

The product should be stored refrigerated at 2‑8 °C, protected from light, and should not be frozen or shaken. It must be kept in its original packaging until preparation, and handling should follow aseptic techniques to maintain sterility before intravenous infusion.

Oxaliplatine Hospira is supplied as an intravenous solution and is given by infusion into a vein, usually over a period of 2 hours. The infusion is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion‑related reactions.

Serious risks include severe peripheral neuropathy that may become irreversible, acute allergic or anaphylactic reactions, significant myelosuppression leading to infection or bleeding, and rare hepatic toxicity. Patients should be monitored closely for these events, and treatment should be modified or stopped if they occur.

Oxaliplatine Hospira should be avoided in individuals with known hypersensitivity to oxaliplatin or other platinum compounds, in patients with severe renal impairment, and in those who are pregnant or breastfeeding unless the benefits clearly outweigh the risks. Clinicians must assess each patient’s medical history before initiating therapy.